SoFi shares rise as record revenue, member growth drive strong Q3 results
Sarah Nemec, Senior VP, Finance and PAO at Bolt Biotherapeutics (NASDAQ:BOLT), reported purchasing 125 shares of common stock at a price of $5.492 on June 6, 2025, for a total value of $686. The purchase comes as the company, currently valued at $11.54 million, trades near $6 per share. According to InvestingPro analysis, BOLT appears undervalued, with strong liquidity and more cash than debt on its balance sheet.
According to a Form 4 filing with the Securities and Exchange Commission, Nemec also acquired 23,000 shares of Bolt Biotherapeutics on October 22, 2025. The shares represent restricted stock units received as an award for no consideration. With the stock down over 46% year-to-date, InvestingPro subscribers can access 8 additional key insights about BOLT’s financial health and valuation metrics.
In other recent news, Bolt Biotherapeutics announced a delay in the clinical data for its cancer immunotherapy candidate, BDC-4182, now expected in the third quarter of 2026. This adjustment comes as the company modifies its trial protocol to incorporate step-up dosing after observing a strong immune response at initial dose levels. Additionally, Bolt Biotherapeutics has decided to cut its workforce by half, reflecting a shift in its operational strategy. On the analyst front, H.C. Wainwright initiated coverage on Bolt Biotherapeutics with a Buy rating and set a price target of $7.00. Meanwhile, Leerink Partners lowered its price target for the company from $20.00 to $6.00, maintaining a Market Perform rating. Leerink Partners highlighted concerns over Bolt’s limited cash runway, emphasizing the importance of securing a partnership for BDC-3042. These recent developments provide investors with a clearer picture of the company’s current challenges and strategic adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.